Cargando…

Anti-GD2 Based Immunotherapy Prevents Late Events in High-Risk Neuroblastoma Patients over 18 Months at Diagnosis

SIMPLE SUMMARY: High-risk neuroblastoma accounts for 4% of newly diagnosed pediatric malignancies, but for 9–10% of pediatric cancer mortality. To reduce the number of (late) recurrences and subsequently improve survival, anti-GD2 monoclonal antibody based immunotherapy has been added to the mainten...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tas, Michelle L., Dootjes, Lisa W., Fiocco, Marta, de Krijger, Ronald R., Dierselhuis, Miranda P., van Eijkelenburg, Natasha K. A., van Grotel, Martine, Kraal, Kathelijne C. J. M., Peek, Annemarie M. L., Tytgat, Godelieve A. M., van Noesel, Max M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507806/ https://www.ncbi.nlm.nih.gov/pubmed/34638426 http://dx.doi.org/10.3390/cancers13194941

Ejemplares similares

Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients
por: Blom, Thomas, et al.
Publicado: (2021)

Refractory Stage M Ganglioneuroblastoma With Bone Metastases and a Favorable, Chronic Course of Disease: Description of a Patient Cohort
por: Tas, Michelle L., et al.
Publicado: (2022)

Immune Monitoring during Therapy Reveals Activitory and Regulatory Immune Responses in High-Risk Neuroblastoma
por: Szanto, Celina L., et al.
Publicado: (2021)

IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models
por: Stip, Marjolein C, et al.
Publicado: (2023)

[(18)F]mFBG PET-CT for detection and localisation of neuroblastoma: a prospective pilot study
por: Samim, Atia, et al.
Publicado: (2022)

Correction to: [(18)F]mFBG PET‑CT for detection and localisation of neuroblastoma: a prospective pilot study
por: Samim, Atia, et al.
Publicado: (2023)

Nuclear Medicine Imaging in Neuroblastoma: Current Status and New Developments
por: Samim, Atia, et al.
Publicado: (2021)

Case series on clinical applications of liquid biopsy in pediatric solid tumors: towards improved diagnostics and disease monitoring
por: Gelineau, Nina U., et al.
Publicado: (2023)

Mesenchymal Neuroblastoma Cells Are Undetected by Current mRNA Marker Panels: The Development of a Specific Neuroblastoma Mesenchymal Minimal Residual Disease Panel
por: van Wezel, Esther M., et al.
Publicado: (2019)

Cisplatin and carboplatin pharmacokinetics in a pediatric patient with hepatoblastoma receiving peritoneal dialysis
por: Nijstad, A. Laura, et al.
Publicado: (2020)

Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels
por: Duijkers, Floor A. M., et al.
Publicado: (2011)

Imaging features of hepatic sinusoidal obstruction syndrome or veno-occlusive disease in children
por: Bohte, Anneloes E., et al.
Publicado: (2021)

Improving Risk Stratification for Pediatric Patients with Rhabdomyosarcoma by Molecular Detection of Disseminated Disease
por: Lak, Nathalie S.M., et al.
Publicado: (2021)

Fenretinide induces mitochondrial ROS and inhibits the mitochondrial respiratory chain in neuroblastoma
por: Cuperus, Roos, et al.
Publicado: (2009)

MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma
por: Eleveld, Thomas F., et al.
Publicado: (2023)

Anti-GD2-IRDye800CW as a targeted probe for fluorescence-guided surgery in neuroblastoma
por: Wellens, Lianne M., et al.
Publicado: (2020)

Urinary 3-Methoxytyramine Is a Biomarker for MYC Activity in Patients With Neuroblastoma
por: Verly, Iedan R. N., et al.
Publicado: (2022)

G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment
por: Martinez Sanz, Paula, et al.
Publicado: (2021)

MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis
por: Bleeker, Gitta, et al.
Publicado: (2014)

Response to: Correspondence on "G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment" by Mora et al
por: Martinez Sanz, Paula, et al.
Publicado: (2021)

Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma
por: Chan, Godfrey Chi-Fung, et al.
Publicado: (2022)

GD2 Expression in Medulloblastoma and Neuroblastoma for Personalized Immunotherapy: A Matter of Subtype
por: Paret, Claudia, et al.
Publicado: (2022)

Characteristics and Outcome of Children with Wilms Tumor Requiring Intensive Care Admission in First Line Therapy
por: Steur, Anouk, et al.
Publicado: (2022)

Neuroblastoma and DIPG Organoid Coculture System for Personalized Assessment of Novel Anticancer Immunotherapies
por: M. Kholosy, Waleed, et al.
Publicado: (2021)

The Metastatic Bone Marrow Niche in Neuroblastoma: Altered Phenotype and Function of Mesenchymal Stromal Cells
por: Hochheuser, Caroline, et al.
Publicado: (2020)

Two opposing gene expression patterns within ATRX aberrant neuroblastoma
por: van Gerven, Michael R., et al.
Publicado: (2023)

The role of (131)I-metaiodobenzylguanidine (MIBG) therapy in unresectable and compromising localised neuroblastoma
por: Schoot, Reineke A., et al.
Publicado: (2013)

Mutational spectrum of ATRX aberrations in neuroblastoma and associated patient and tumor characteristics
por: van Gerven, Michael R., et al.
Publicado: (2022)

Correction to: Perfusion imaging of neuroblastoma and nephroblastoma in a paediatric population using pseudo‑continuous arterial spin‑labelling magnetic resonance imaging
por: Harteveld, Anita, et al.
Publicado: (2021)

Mesenchymal Stromal Cells in Neuroblastoma: Exploring Crosstalk and Therapeutic Implications
por: Hochheuser, Caroline, et al.
Publicado: (2021)

Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma
por: Spel, Lotte, et al.
Publicado: (2015)

Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy
por: Liu, Xiaoming, et al.
Publicado: (2022)

Perfusion imaging of neuroblastoma and nephroblastoma in a paediatric population using pseudo-continuous arterial spin-labelling magnetic resonance imaging
por: Harteveld, Anita Adriaantje, et al.
Publicado: (2021)

Selective serotonin reuptake inhibitors (SSRIs) prevent meta-iodobenzylguanidine (MIBG) uptake in platelets without affecting neuroblastoma tumor uptake
por: Blom, Thomas, et al.
Publicado: (2020)

The Potential of Mesenchymal Stromal Cells in Neuroblastoma Therapy for Delivery of Anti-Cancer Agents and Hematopoietic Recovery
por: Hochheuser, Caroline, et al.
Publicado: (2021)

Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma
por: Kroesen, Michiel, et al.
Publicado: (2016)

Anti-GD2 antibody and Vorinostat immunocombination therapy is highly effective in an aggressive orthotopic neuroblastoma model
por: van den Bijgaart, Renske J. E., et al.
Publicado: (2020)

Thrombocytopenia after meta-iodobenzylguanidine (MIBG) therapy in neuroblastoma patients may be caused by selective MIBG uptake via the serotonin transporter located on megakaryocytes
por: Blom, Thomas, et al.
Publicado: (2021)

Detection of GD2-positive cells in bone marrow samples and survival of patients with localised neuroblastoma
por: Corrias, M V, et al.
Publicado: (2008)

Mechanism of effective combination radio-immunotherapy against 9464D-GD2, an immunologically cold murine neuroblastoma
por: Aiken, Taylor J, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1d3j09krs0b5qrgij6sltuqpne